Article Details
Retrieved on: 2024-12-13 18:26:35
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses how the European Medicines Agency decided Eli Lilly's Mounjaro (Tirzepatide) for obesity doesn't need a separate indication for treating obstructive sleep apnea. It already improves sleep-disordered breathing through weight reduction, benefiting patients with diabetes-related obesity. The inclusion of this data in product information highlights its effects on related sleep disorders.
Article found on: sleepreviewmag.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here